Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.

Journal

Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519

Informations de publication

Date de publication:
Feb 2020
Historique:
pubmed: 9 1 2020
medline: 9 1 2020
entrez: 9 1 2020
Statut: ppublish

Résumé

In the original publication of the article, the authors wish to note an error in the section "Funding".

Identifiants

DOI: 10.1007/s00280-019-04026-7 PMID: 31912224
pubmed: 31912224
doi: 10.1007/s00280-019-04026-7
pii: 10.1007/s00280-019-04026-7
doi:

Types de publication

Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

475

Commentaires et corrections

Type : ErratumFor

Auteurs

Samuel J Reddick (SJ)

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA.

Olivia Campagne (O)

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA.

Jie Huang (J)

Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.

Arzu Onar-Thomas (A)

Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.

Alberto Broniscer (A)

Division of Neuro-Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Amar Gajjar (A)

Division of Neuro-Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Clinton F Stewart (CF)

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA. clinton.stewart@stjude.org.

Classifications MeSH